Legal Status
Legal Status
Rule
Advisory Committee; Change of Name and Function; Technical Amendment
A Rule by the Food and Drug Administration on
Document Details
Information about this document as published in the Federal Register.
- Printed version:
- Publication Date:
- 08/30/2011
- Agencies:
- Food and Drug Administration
- Dates:
- Effective September 6, 2011.
- Effective Date:
- 09/06/2011
- Document Type:
- Rule
- Document Citation:
- 76 FR 53816
- Page:
- 53816-53817 (2 pages)
- CFR:
- 21 CFR 14
- Agency/Docket Number:
- Docket No. FDA-2011-N-0002
- Document Number:
- 2011-22105
Document Details
-
Enhanced Content - Table of Contents
This tables of contents is a navigational tool, processed from the headings within the legal text of Federal Register documents. This repetition of headings to form internal navigation links has no substantive legal effect.
Enhanced Content - Table of Contents
-
Enhanced Content - Submit Public Comment
- This feature is not available for this document.
Enhanced Content - Submit Public Comment
-
Enhanced Content - Read Public Comments
- This feature is not available for this document.
Enhanced Content - Read Public Comments
-
Enhanced Content - Sharing
- Shorter Document URL
- https://www.federalregister.gov/d/2011-22105 https://www.federalregister.gov/d/2011-22105
Enhanced Content - Sharing
-
Enhanced Content - Document Tools
These tools are designed to help you understand the official document better and aid in comparing the online edition to the print edition.
-
These markup elements allow the user to see how the document follows the Document Drafting Handbook that agencies use to create their documents. These can be useful for better understanding how a document is structured but are not part of the published document itself.
Display Non-Printed Markup Elements
Enhanced Content - Document Tools
-
-
Enhanced Content - Developer Tools
This document is available in the following developer friendly formats:
- JSON: Normalized attributes and metadata
- XML: Original full text XML
- MODS: Government Publishing Office metadata
More information and documentation can be found in our developer tools pages.
Enhanced Content - Developer Tools
Published Document
This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.
AGENCY:
Food and Drug Administration, HHS.
ACTION:
Final rule.
SUMMARY:
The Food and Drug Administration (FDA) is amending the standing advisory committees' regulations to change the name and function of the Anesthetic and Life Support Drugs Advisory Committee. This action is being taken to reflect changes made to the charter for this advisory committee.
DATES:
Effective September 6, 2011.
Start Further InfoFOR FURTHER INFORMATION CONTACT:
Philip Bautista, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 31, Rm. 2417, Silver Spring, MD 20993-0002, 301-796-9001.
End Further Info End Preamble Start Supplemental InformationSUPPLEMENTARY INFORMATION:
FDA is announcing that the name of the Anesthetic and Life Support Drugs Advisory Committee, which was established on May 1, 1978, has been changed. The Agency decided that the name “Anesthetic and Analgesic Drug Products Advisory Committee” would more accurately describe the subject areas for which the committee is responsible. The mandate of the committee is being expanded to include analgesics, e.g., abuse-deterrent opioids, novel analgesics, and opioid abuse.
The Committee reviews and evaluates available data concerning the safety and effectiveness of marketed and investigational human drug products including analgesics, e.g., abuse-deterrent opioids, novel analgesics, and issues related to opioid abuse, and those for use in anesthesiology.
The Anesthetic and Life Support Drugs Advisory Committee name was changed and its functions expanded in the charter renewal dated June 9, 2011. FDA is hereby revising 21 CFR 14.100 (c)(1) to reflect these changes.
Publication of this final rule constitutes a final action on this change under the Administrative Procedure Act. Under 5 U.S.C. 553(b)(3)(B) and (d) and 21 CFR 10.40(d) and (e), the Agency finds good cause to dispense with notice and public procedure and to proceed to an immediately effective regulation. Such notice and procedures are unnecessary and are not in the public interest, because the final rule is merely codifying the new name and the expanded function of the advisory committee to reflect the current committee charter.
Start List of SubjectsList of Subjects in 21 CFR Part 14
- Administrative practice and procedure
- Advisory committees
- Color additives
- Drugs
- Radiation protection
Therefore, under the Federal Food and Drug, and Cosmetic Act and under Start Printed Page 53817authority delegated to the Commissioner of Food and Drugs, 21 CFR part 14 is amended as follows:
Start PartPART 14—PUBLIC HEARING BEFORE A PUBLIC ADVISORY COMMITTEE
End Part Start Amendment Part1. The authority citation for
End Amendment Part Start AuthorityAuthority: 5 U.S.C. App. 2; 15 U.S.C. 1451-1461; 21 U.S.C. 41-50, 141-149, 321-394, 467f, 679, 821, 1034; 28 U.S.C. 2112; 42 U.S.C. 201, 262, 263b, 264; Pub. L. 107-109, Pub. L. 108-155.
End Authority Start Amendment Part2. Section 14.100 is amended by revising the heading of paragraph (c)(1) and paragraph (c)(1)(ii) to read as follows:
End Amendment Part(c) * * *
(1) Anesthetic and Analgesic Drug Products Advisory Committee.
(ii) Function: Reviews and evaluates data concerning the safety and effectiveness of marketed and investigational human drug products including analgesics, e.g., abuse-deterrent opioids, novel analgesics, and issues related to opioid abuse, and those for use in anesthesiology.
Dated: August 25, 2011.
Jill Hartzler Warner,
Acting Associate Commissioner for Special Medical Programs.
[FR Doc. 2011-22105 Filed 8-29-11; 8:45 am]
BILLING CODE 4160-01-P